Loading...
XNASBLFS
Market cap1.23bUSD
Jan 10, Last price  
26.61USD
1D
-3.90%
1Q
17.74%
Jan 2017
1,552.49%
Name

BioLife Solutions Inc

Chart & Performance

D1W1MN
XNAS:BLFS chart
P/E
P/S
8.62
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
21.88%
Rev. gr., 5y
48.65%
Revenues
143m
-11.43%
626,709614,718603,219972,2621,322,4971,581,6002,081,5652,758,7295,662,9908,949,4016,190,6986,448,9108,227,00011,022,00019,742,00027,371,00048,087,000119,156,000161,759,000143,271,000
Net income
-66m
L-52.49%
-743,162-619,323-1,134,018-2,851,774-2,775,117-2,768,352-1,983,630-1,956,639-1,659,586-1,084,160-3,217,750-4,213,936-6,875,000-2,515,0003,266,00011,062,0002,667,000-8,383,000-139,805,000-66,427,000
CFO
-12m
L+47.23%
515,104-576,333-712,196-2,708,979-2,113,418-2,413,642-1,252,526-989,917854,934146,007-3,162,316-4,973,861-4,327,000605,0002,348,0001,213,0006,515,000-4,836,000-8,489,000-12,498,000
Earnings
Feb 26, 2025

Profile

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
IPO date
Nov 22, 1989
Employees
466
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122015‑01
Income
Revenues
143,271
-11.43%
161,759
35.75%
Cost of revenue
195,623
191,975
Unusual Expense (Income)
NOPBT
(52,352)
(30,216)
NOPBT Margin
Operating Taxes
169
(5,022)
Tax Rate
NOPAT
(52,521)
(25,194)
Net income
(66,427)
-52.49%
(139,805)
1,567.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,244
(131)
BB yield
-1.44%
0.02%
Debt
Debt current
13,179
4,832
Long-term debt
50,232
56,987
Deferred revenue
Other long-term liabilities
2,328
Net debt
6,099
(8,647)
Cash flow
Cash from operating activities
(12,498)
(8,489)
CAPEX
(6,381)
(10,385)
Cash from investing activities
17,837
(58,117)
Cash from financing activities
10,591
16,317
FCF
11,627
(18,196)
Balance
Cash
51,695
64,065
Long term investments
5,617
6,401
Excess cash
50,148
62,378
Stockholders' equity
(313,642)
(247,551)
Invested Capital
697,169
41,551
ROIC
ROCE
EV
Common stock shares outstanding
43,719
42,481
Price
16.25
-10.71%
18.20
-51.17%
Market cap
710,437
-8.11%
773,155
-46.12%
EV
716,536
764,508
EBITDA
(40,057)
(13,744)
EV/EBITDA
Interest
1,812
687
Interest/NOPBT